Results from an Italian Phase 1/2 trial show that a combination therapy consisting of lower doses of Velcade, melphalan, and prednisone may be an effective and safe salvage therapy for older multiple myeloma patients.

Over half of the patients in the trial responded to the treatment, and according to the study investigators, the treatment was well tolerated, making it a viable treatment option for older myeloma patients.

In Europe, the combination treatment of Velcade (bortezomib), melphalan (Alkeran), and prednisone – commonly referred to as VMP – is often given as initial therapy to …